Sanofi ADR

NASDAQ: SNY
$47.82
-$1.69 (-3.4%)
Closing Price on November 14, 2024

SNY Articles

The number of COVID-19 cases continues to rise, which will only create more demand for coronavirus stocks. 24/7 Wall Street has picked out a few of the best and brightest that could still see a big...
24/7 Wall Street has picked out a few of the best and brightest coronavirus stocks that could still see a big push as 2020 continues.
Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July 2020.
Sanofi and Translate Bio are making waves in the fight against the novel coronavirus as the two have agreed to expand their existing 2018 collaboration and license agreement
Sanofi's announcement that it would be investing in a COVID-19 vaccine production site in France gave shares a boost early Tuesday.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
U.S. consumer confidence continues to decline, but the slide has slowed. On Sunday, the FDA and the Department of Health and Human Services okayed two drugs for use in the fight against COVID-19.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this coronavirus and here is where their stocks stand now.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this novel coronavirus. Here's how they fared as the week wound down.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
Wednesday's top analyst upgrades, downgrades and initiations included Accenture, Anheuser-Busch InBev, Cerner, CNOOC, Delta Air Lines, Ford, GoDaddy, Kinder Morgan, Newmont, NuStar, United Airlines...
Wednesday's top analyst upgrades, downgrades and initiations included AECOM, Albermarle, Apple, Chesapeake Energy, Foot Locker, Gap, GoPro, Nike, Qualcomm, Southwest Airlines, Under Armour and...
After Lexicon Pharmaceuticals announced the termination of its alliance with Sanofi, its shares rallied on Wednesday.
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February and March.
The included top analyst upgrades, downgrades and initiations seen on Tuesday Apptio, AT&T, Bain Capital, Comerica, First Solar, Palo Alto Networks, Pfizer, Travelers and Ulta Beauty.